Effects of omalizumab treatment in patients with refractory chronic urticaria

Allergy, Asthma and Immunology Research

Volumn 4, Issue 6, 2012, Pages 357-361

  Nam, Young Hee ^a   Kim, Joo Hee ^b   Jin, Hyun Jung ^a   Hwang, Eui Kyung ^a   Shin, Yoo Seob ^a   Ye, Young Min ^a   Park, Hae Sim ^a  

^a Ajou University School of Medicine   (South Korea)

^b Hallym University College of Medicine   (South Korea)

Author keywords

Chronic urticaria; Omalizumab; Refractory

Indexed keywords

ANTIHISTAMINIC AGENT; COLCHICINE; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN E; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LORATADINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; STEROID;

ADULT; ARTICLE; BODY WEIGHT; CHRONIC URTICARIA; CLINICAL ARTICLE; DRUG EFFICACY; FAMILY HISTORY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; QUALITY OF LIFE; REMISSION;

EID: 84869752751     PISSN: 20927355     EISSN: 20927363     Source Type: Journal    
DOI: 10.4168/aair.2012.4.6.357     Document Type: Article

References (34)

1. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, Grattan CE, Kapp A, Merk HF, Rogala B, Saini S, Sánchez-Borges M, Schmid-Grendelmeier P, Schünemann H, Staubach P, Vena GA, Wedi B, Maurer M Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009;64:1417-26.
2. Greaves MW. Chronic urticaria. N Engl J Med 1995;332:1767-72.
3. Hellgren L. The prevalence of urticaria in the total population. Acta Allergol 1972;27:236-40.
4. Gaig P, Olona M, Muñoz Lejarazu D, Caballero MT, Domínguez F, Echechipia S, García Abujeta JL, Gonzalo MA, Lleonart R, Martínez Cócera C, Rodríguez A, Ferrer M. Epidemiology of urticaria in Spain. J Investig Allergol Clin Immunol 2004;14:214-20.
5. Baiardini I, Giardini A, Pasquali M, Dignetti P, Guerra L, Specchia C, Braido F, Majani G, Canonica GW. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 2003; 58:621-3.
6. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997; 136:197-201.
7. Caine N, Harrison SC, Sharples LD, Wallwork J. Prospective study of quality of life before and after coronary artery bypass grafting. BMJ 1991;302:511-6.
8. Yosipovitch G, Ansari N, Goon A, Chan YH, Goh CL. Clinical characteristics of pruritus in chronic idiopathic urticaria. Br J Dermatol 2002;147:32-6.
9. Delong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol 2008;144:35-9.
10. Kapp A, Demarteau N. Cost effectiveness of levocetirizine in chronic idiopathic urticaria: a pooled analysis of two randomised controlled trials. Clin Drug Investig 2006;26:1-11.
11. Grattan CE, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol 2002;46:645-57; quiz 57-60.
12. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003;3:363-8.
13. Sabroe RA, Fiebiger E, Francis DM, Maurer D, Seed PT, Grattan CE, Black AK, Stingl G, Greaves MW, Barr RM. Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 2002;110:492-9.
14. Vichyanond P. Omalizumab in allergic diseases, a recent review. Asian Pac J Allergy Immunol 2011;29:209-19.
15. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008;122:569-73.
16. Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, Spector S, Maurer M. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol 2011; 128:567-73.e1.
17. Groffik A, Mitzel-Kaoukhov H, Magerl M, Maurer M, Staubach P. Omalizumab--an effective and safe treatment of therapy-resistant chronic spontaneous urticaria. Allergy 2011;66:303-5.
18. Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008;63:247-9.
19. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez -Arnau AM, Grattan CE, Kapp A, Maurer M, Merk HF, Rogala B, Saini S, Sánchez -Borges M, Schmid-Grendelmeier P, Schünemann H, Staubach P, Vena GA, Wedi B Dermatology Section of the European Academy of Allergology and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64:1427-43.
20. Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol 2011;128:202-9.e5.
21. Ye YM, Park JW, Kim SH, Choi JH, Hur GY, Lee HY, Lee EH, Park HS. Clinical evaluation of the computerized Chronic Urticaria-Specific Quality of Life questionnaire in Korean patients with chronic urticaria. Clin Exp Dermatol. Forthcoming 2012.
22. Lee EH, Park JW, Kim C, Kim SH, Lee Y, Choi JH, Ye YM, Park HS. Development and psychometric evaluation of chronic urticaria-specific quality of life scale (CU-QOL) [abstract]. Korean J Asthma Allergy Clin Immunol 2010;30 Suppl 2:S384.
23. Palikhe NS, Kim SH, Ye YM, Hur GY, Cho BY, Park HS. Association of CRTH2 gene polymorphisms with the required dose of antihistamines in patients with chronic urticaria. Pharmacogenomics 2009;10:375-83.
24. Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, Kapp A, Kozel MM, Maurer M, Merk HF, Schäfer T, Simon D, Vena GA, Wedi B EAACI/GA2LEN/EDF. EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy 2006;61: 321-31.
25. Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998;138:635-8.
26. Grattan CE, Humphreys F; British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for evaluation and management of urticaria in adults and children. Br J Dermatol 2007;157:1116-23.
27. Ferrer M, Gamboa P, Sanz ML, Goikoetxea MJ, Cabrera-Freitag P, Javaloyes G, Berroa F, Kaplan AP. Omalizumab is effective in nonautoimmune urticaria. J Allergy Clin Immunol 2011;127:1300-2.
28. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, Canonica GW, Church MK, Godse KV, Grattan CE, Greaves MW, Hide M, Kalogeromitros D, Kaplan AP, Saini SS, Zhu XJ, Zuberbier T. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 2011;66:317-30.
29. Toubi E, Kessel A, Avshovich N, Bamberger E, Sabo E, Nusem D, Panasoff J. Clinical and laboratory parameters in predicting chronic urticaria duration: a prospective study of 139 patients. Allergy 2004;59:869-73.
30. Champion RH, Roberts SO, Carpenter RG, Roger JH. Urticaria and angio-oedema. A review of 554 patients. Br J Dermatol 1969;81: 588-97.
31. Caproni M, Volpi W, Giomi B, Cardinali C, Antiga E, Melani L, Dagata A, Fabbri P. Chronic idiopathic and chronic autoimmune urticaria: clinical and immunopathological features of 68 subjects. Acta Derm Venereol 2004;84:288-90.
32. Metz M, Giménez-Arnau A, Borzova E, Grattan CE, Magerl M, Maurer M. Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. J Allergy Clin Immunol 2009;123:705-6.
33. Tanaka T, Kameyoshi Y, Hide M. Analysis of the prevalence of subtypes of urticaria and angioedema. Arerugi 2006;55:134-9.
34. van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol 2002;146:110-3.